Article
Immunology
Michele Aramburu Serafini, Dienifer Hermann Sirena, Ana Beatriz Tittoni da Silveira, Monique Franco-da-Silva, Mariana Rauback Aubin, Tuane Nerissa Alves Garcez, Anelise Araujo, Fernanda dos Santos Pereira, Martin J. Hoogduijn, Fabiany da Costa Goncalves, Ana Helena Paz
Summary: Inflammatory bowel diseases (IBD), including ulcerative colitis, are chronic inflammations of the gastrointestinal tract. Mesenchymal stromal cells (MSC) have shown promise as a therapy for IBD, but practical complexities arise from using living cells. This study investigated the potential of MSC-derived membrane particles (MP) and conditioned media (CM) as cell-free therapies for IBD, and found that they ameliorated colitis symptoms in a mouse model.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Review
Immunology
Zhengping Che, Ziyu Ye, Xueying Zhang, Bihua Lin, Weiqing Yang, Yanfang Liang, Jincheng Zeng
Summary: Inflammatory bowel diseases (IBDs) are a group of chronic inflammatory disorders of the gastrointestinal tract. Current treatments are not fully curative and often lead to relapse. Mesenchymal stem/stromal cells (MSCs), with their multipotent differentiation and immunomodulatory capabilities, show potential for the treatment of IBDs.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Pharmacology & Pharmacy
Andrea Cassinotti, Francesco Passamonti, Sergio Segato
Summary: Cell-based therapies have been explored in immune-mediated inflammatory diseases, including inflammatory bowel disease (IBD). The most studied treatment in IBD involves stem cells, with recent studies also focusing on regulatory cells such as T-reg and Tr1 cells. Preclinical research is also being conducted on induced pluripotent stem cells in animal models related to colitis.
PHARMACOLOGICAL RESEARCH
(2021)
Review
Biochemistry & Molecular Biology
Jeffrey Zheng-Hsien Ko, Sheeva Johnson, Maneesh Dave
Summary: Inflammatory bowel disease is a chronic inflammatory disorder of the gut. Mesenchymal stem/stromal cells are being explored as a novel therapy for this condition, showing promising safety and effectiveness, particularly for perianal fistulizing Crohn's disease. Recent studies support the long-term efficacy of local MSC injection for PFCD, while the evidence for systemic MSC infusion in luminal IBD remains mixed.
Review
Biochemistry & Molecular Biology
Hua-Min Zhang, Shuo Yuan, Huan Meng, Xiao-Ting Hou, Jiao Li, Jia-Chen Xue, You Li, Qi Wang, Ji-Xing Nan, Xue-Jun Jin, Qing-Gao Zhang
Summary: Inflammatory bowel disease (IBD) is a chronic, relapsing disease that greatly affects patients' quality of life. Stem cell therapy has shown potential to improve the clinical disease activity of patients with refractory IBD when conventional treatments are not effective, but its safety and long-term efficacy need further evaluation.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Cell Biology
Trinidad Montero-Vilchez, Alvaro Sierra-Sanchez, Manuel Sanchez-Diaz, Maria Isabel Quinones-Vico, Raquel Sanabria-de-la-Torre, Antonio Martinez-Lopez, Salvador Arias-Santiago
Summary: Mesenchymal stromal cell-conditioned medium (MSC-CM) shows promising potential in treating skin conditions by improving wound healing, hair restoration, skin rejuvenation, and some inflammatory skin diseases. Further research is needed to confirm its safety, effectiveness, and to standardize the manufacturing process.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Multidisciplinary Sciences
Guopu Chen, Fengyuan Wang, Min Nie, Hui Zhang, Han Zhang, Yuanjin Zhao
Summary: The newly developed roe-inspired microcapsules, providing sufficient nutrient supply and maintaining the functions of mesenchymal stem cells through core-shell structure, have the potential for clinical application in treating inflammatory bowel disease.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2021)
Review
Biochemistry & Molecular Biology
Mercedes Lopez-Santalla, Marina Inmaculada Garin
Summary: Inflammatory bowel diseases (IBD) are characterized by persistent and relapsing inflammatory processes, with genetic, environmental, and commensal microbiota factors playing a role. Current biological treatments have some drawbacks, leading to the need for novel effective therapies. Mesenchymal stem/stromal cell (MSCs) therapy has shown promise preclinically, but successful results have not always been replicated in clinical trials. New approaches are being explored to enhance the beneficial effects of MSC-based therapy for IBD.
Article
Cell & Tissue Engineering
Murugadas Anbazhagan, Duke Geem, Suresh Venkateswaran, Ranjit Pelia, Vasantha L. Kolachala, Anne Dodd, Sushma C. Maddipatla, David J. Cutler, Jason D. Matthews, Raghavan Chinnadurai, Subra Kugathasan
Summary: Autologous intestinal MSCs from patients with inflammatory bowel disease (IBD) exhibit normal transcriptional and immunomodulatory properties, indicating their potential for cellular therapy.
STEM CELLS TRANSLATIONAL MEDICINE
(2023)
Review
Pharmacology & Pharmacy
Florian Draguet, Cyril Bouland, Nathan Dubois, Dominique Bron, Nathalie Meuleman, Basile Stamatopoulos, Laurence Lagneaux
Summary: Intercellular communication is crucial in multicellular organisms, and in recent years, extracellular vesicles (EVs) have emerged as a new communication mechanism. MSC-derived EVs have shown great potential as therapeutic agents, with advantages such as biocompatibility, stability in circulation, and the ability to cross biological barriers. They also have potential for drug delivery.
Review
Medicine, Research & Experimental
Mohamed J. Saadh, Maria V. Mikhailova, Soheil Rasoolzadegan, Mojgan Falaki, Roozbeh Akhavanfar, Jose Luis Arias Gonzales, Amir Rigi, Bahman Abedi Kiasari
Summary: Introduces the emerging therapeutic modality of mesenchymal stem/stromal cells (MSCs) therapy for the treatment of inflammatory bowel disease (IBD). MSCs alleviate dysregulated inflammatory responses through the secretion of anti-inflammatory mediators and their effects on gut immuno-microbiota regulation and the proliferation and differentiation of intestinal cells. Clinical trials are being conducted to evaluate the safety and efficacy of MSCs administration in IBD patients.
EUROPEAN JOURNAL OF MEDICAL RESEARCH
(2023)
Review
Nutrition & Dietetics
Jose M. Comeche, Ana Gutierrez-Hervas, Jose Tuells, Cesare Altavilla, Pablo Caballero
Summary: Predefined diets have shown partial efficacy in treating inflammatory bowel disease, although doubts exist regarding specific indicators. Further research is needed to evaluate the influence of predefined diets on IBD patients.
Review
Pharmacology & Pharmacy
Rashi Srivastava, Aidong Li, Tirtharaj Datta, Niraj Kumar Jha, Salehikram Talukder, Saurabh Kumar Jha, Zhe-Sheng Chen
Summary: Deposition of misfolded proteins and synaptic failure in Alzheimer's disease lead to memory loss and cognitive impairment. Stromal cells show potential as a treatment for AD due to their pluripotency and ability to differentiate into nerve cells and glial cells. Successful evidence in animal models and promising clinical trials suggest the use of stromal cell therapy, but further research is needed.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Pharmacology & Pharmacy
Sara Rolandsson Enes, Anna D. Krasnodembskaya, Karen English, Claudia C. Dos Santos, Daniel J. Weiss
Summary: Advancements in cell-based therapies for lung diseases and critical illnesses show promise, but translating efficacy from preclinical to clinical settings has been challenging due to limited understanding of MSCs' interaction with the host environment. Challenges for MSC cell therapies include cell sources, dosing, disease targets, donor variability, and cell product manufacturing.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Immunology
Max A. Skibber, Scott D. Olson, Karthik S. Prabhakara, Brijesh S. Gill, Charles S. Cox
Summary: Mechanotransduction, achieved by exposing MSC to various grades of wall shear stress (WSS), enhances their immunomodulatory potential independent of classical pro-inflammatory cytokines. The study suggests biomechanical conditioning as a viable and scalable pre-conditioning alternative to enhance the immunomodulatory capacity of MSC in cell therapy manufacturing.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Gastroenterology & Hepatology
Sophie Vieujean, Jean-Philippe Loly, Layla Boutaffala, Paul Meunier, Catherine Reenaers, Alexandra Briquet, Chantal Lechanteur, Etienne Baudoux, Yves Beguin, Edouard Louis
Summary: This study evaluated the safety and efficacy of mesenchymal stem cell (MSC) injection for the treatment of Crohn's disease strictures. The results showed that MSC injection may be a safe and effective approach for complete or partial resolution of the strictures.
JOURNAL OF CROHNS & COLITIS
(2022)
Article
Gastroenterology & Hepatology
Morgan Vandermeulen, Maleyko Mohamed-Wais, Pauline Erpicum, Marie-Helene Delbouille, Chantal Lechanteur, Alexandra Briquet, Gianni Maggipinto, Francois Jouret, Yves Beguin, Olivier Detry
Summary: The study confirmed the safety of a single MSC infusion after LT with no significant increase in infection or cancer risk, but a higher incidence of liver DSAs in the MSC group. Further evaluation of anti-HLA antibodies against MSC donors is warranted.
LIVER TRANSPLANTATION
(2022)
Correction
Critical Care Medicine
Nicolas Massart, Virginie Maxime, Pierre Fillatre, Keyvan Razazi, Alexis Ferre, Pierre Moine, Francois Legay, Guillaume Voiriot, Marlene Amara, Francesca Santi, Saad Nseir, Stephanie Marque-Juillet, Rania Bounab, Nicolas Barbarot, Fabrice Bruneel, Charles-Edouard Luyt
ANNALS OF INTENSIVE CARE
(2022)
Article
Multidisciplinary Sciences
Pascale Huynen, Celine Gregoire, Stephanie Gofflot, Laurence Seidel, Nathalie Maes, Laura Vranken, Sandra Delcour, Michel Moutschen, Marie-Pierre Hayette, Philippe Kolh, Pierrette Melin, Yves Beguin
Summary: Asymptomatic and pauci-symptomatic cases contribute to underestimating the prevalence of SARS-CoV-2 infections. Few studies have been conducted on the longitudinal follow-up of SARS-CoV-2 antibodies after natural infection. The study found that IgM antibodies could still be detected after 6 weeks of infection, and the majority of participants had sustained high levels of IgG antibodies after 12 weeks.
SCIENTIFIC REPORTS
(2022)
Article
Oncology
Edouard Forcade, Solenn Bacquet, Caroline Ballot, Lucille Capin, Federico Garnier, Christine Giraud, Marie-Agnes Guerout-Verite, Catherine Letellier, Alessandra Magnani, Anne-Claire Mamez, Justine Nasone, Mahamadou Sinayoko, Etienne Baudoux, Valerie Mialou, Ibrahim Yakoub-Agha, Boris Calmels
Summary: The COVID-19 pandemic disrupted allogeneic stem cell transplantation activities globally, necessitating the cryopreservation of allografts to ensure the procedure's success. Cryopreservation has been widely adopted by French speaking centers, and data from 24 centers were analyzed to assess its impact on allograft quality. The analysis clearly shows that prolonged transit time (over 48 hours) negatively affects CD34' recovery, justifying the slight increase in the requested CD34' cell dose and the importance of quality control for the infused product.
BULLETIN DU CANCER
(2023)
Review
Oncology
David Kegyes, Catalin Constantinescu, Louise Vrancken, Leo Rasche, Celine Gregoire, Bogdan Tigu, Diana Gulei, Delia Dima, Alina Tanase, Hermann Einsele, Stefan Ciurea, Ciprian Tomuleasa, Jo Caers
Summary: Multiple myeloma is an incurable plasma cell malignancy that is affecting an increasing number of patients worldwide. Novel immunotherapies, such as CAR T cell therapy and bispecific T cell engagers, are targeting different surface antigens, but stem cell transplantation remains essential in transplant-eligible patients. Research suggests that early use of immunotherapy can significantly improve outcomes.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2022)
Article
Virology
Majdouline El Moussaoui, Nathalie Maes, Samuel L. Hong, Nicolas Lambert, Stephanie Gofflot, Patricia Dellot, Yasmine Belhadj, Pascale Huynen, Marie-Pierre Hayette, Cecile Meex, Sebastien Bontems, Justine Defeche, Lode Godderis, Geert Molenberghs, Christelle Meuris, Maria Artesi, Keith Durkin, Souad Rahmouni, Celine Gregoire, Yves Beguin, Michel Moutschen, Simon Dellicour, Gilles Darcis
Summary: Healthcare workers, especially nurses, paramedics, and laboratory staff handling respiratory samples, are at higher risk of SARS-CoV-2 infections. Phylogenetic analysis reveals that most positive samples were independently introduced into the hospital.
Article
Multidisciplinary Sciences
Celine Gregoire, Pascale Huynen, Stephanie Gofflot, Laurence Seidel, Nathalie Maes, Laura Vranken, Sandra Delcour, Michel Moutschen, Marie-Pierre Hayette, Philippe Kolh, Pierrette Melin, Yves Beguin
Summary: This study identifies risk factors associated with SARS-CoV-2 transmission and immunization by analyzing data from staff members of a Belgian hospital. Factors such as contact with COVID-19 patients, immunodeficiency, and hematological malignancy are found to be associated with higher seroprevalence.
SCIENTIFIC REPORTS
(2022)
Article
Immunology
Celine Gregoire, Nathalie Layios, Bernard Lambermont, Chantal Lechanteur, Alexandra Briquet, Virginie Bettonville, Etienne Baudoux, Marie Thys, Nadia Dardenne, Benoit Misset, Yves Beguin
Summary: BM-MSC therapy is safe and effective in treating severe COVID-19, with a higher survival rate compared to standard therapy. The use of BM-MSCs shows promise in controlling the immune-mediated inflammatory response associated with severe COVID-19, leading to improved outcomes.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Gastroenterology & Hepatology
Catherine Reenaers, Romain P. Gillard, Carla Coimbra, Rene M. Gillard, Paul Meunier, Chantal Lechanteur, Etienne Baudoux, Layla Boutaffala, Yves Beguin, Edouard Louis
Summary: This study evaluated the safety and clinical efficacy of bone marrow-derived MSC injection for perianal fistulizing CD. It found that the treatment was safe and effective, leading to closure of the fistulae and significant MRI changes.
JOURNAL OF CROHNS & COLITIS
(2023)
Article
Immunology
Sophie Servais, Frederic Baron, Chantal Lechanteur, Laurence Seidel, Etienne Baudoux, Alexandra Briquet, Dominik Selleslag, Johan Maertens, Xavier Poire, Wilfried Schroyens, Carlos Graux, Ann De Becker, Pierre Zachee, Aurelie Ory, Julie Herman, Tessa Kerre, Yves Beguin
Summary: BM-derived MSC from a third-party donor appeared to improve hematological function after alloHCT, but comparative studies are needed to confirm these results.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Critical Care Medicine
Christophe Le Terrier, Florian Sigaud, Said Lebbah, Luc Desmedt, David Hajage, Claude Guerin, Jerome Pugin, Steve Primmaz, Nicolas Terzi
Summary: Prone positioning (PP) is frequently used as a main treatment for intubated ICU patients with COVID-19-induced ARDS. However, early PP within 24 hours of ICU admission does not show a survival benefit compared to PP after day-1.